Evotec AG launched its accelerated drug development service INDiGO(R) to deliver better drug candidates to patients faster and more efficiently than standard industry approaches.
INDiGO(R) is a proven development solution that has been successfully executed by Evotec’s recent acquisition of Aptuit for several years, who are market leaders in providing high-value integrated drug discovery and development solutions. The INDiGO(R) service has been proven to reduce the time and cost of pre-clinical drug development whilst delivering a high-quality data package for CTA/IND level regulatory filings. Typical INDiGO(R) activities include:
- API manufacture, formulation development, clinical supply, safety assessment, DMPK, bioanalysis and biomarkers, and regulatory submission documents preparation.
Evotec’s partners benefit from a single, integrated provider for all required functions and capabilities coupled with best-in-class project management and seasoned scientific leadership.
Dr Mario Polywka, Chief Operating Officer, commented: “Evotec’s INDiGO(R) delivers to our partners a truly integrated approach to accelerate development of their drug candidates to regulatory submission in the most time- and cost-efficient manner. INDiGO(R) allows our customers to seamlessly transition from candidate selection into the regulatory space and to patients efficiently and quickly.”
(Source: Evotec AG)
